Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals (Nasdaq: NRXP) said the U.S. Food and Drug Administration has authorized an Expanded Access Protocol for its investigational depression treatment NRX-101, potentially allowing certain patients …
FDA Clears Expanded Access Path for NRx Depression Therapy Read More
PHOENIXVILLE, PA — PleoPharma has dosed the first patient in a Phase 3 clinical trial of an investigational treatment for cannabis withdrawal symptoms, advancing a drug candidate that could become …
PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug Read More
PLYMOUTH MEETING, PA — Patients with advanced cancer were significantly more likely to discuss and document their care preferences when both they and their physicians received targeted reminders, according to …
Cancer Care Study Finds Targeted Prompts Increase End-of-Life Discussions Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported updated early-stage clinical trial data showing its experimental antibody INCA033989 produced rapid and durable responses in patients with myelofibrosis and essential thrombocythemia, supporting …
Incyte Antibody Shows Disease-Modifying Potential in Blood Cancers Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported Phase III trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death …
Incyte Trial Data Support New First-Line Approach in Lymphoma Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has asked the U.S. Food and Drug Administration to grant Rare Pediatric Disease Designation for its experimental SkinJect therapy in patients with …
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy Read More
NEWARK, DE — N-Zyme Biomedical has begun a Phase 2 clinical trial of its lead drug candidate for laryngopharyngeal reflux, advancing a treatment approach that targets pepsin rather than stomach …
N-Zyme Advances Pepsin-Targeting Reflux Drug Into Phase 2 Trial Read More
WEST CHESTER, PA — Molecular Targeting Technologies Inc. reported updated clinical data from 81 patients with gastroenteropancreatic neuroendocrine tumors treated with its experimental radiopharmaceutical EBTATE, results that the company says …
MTTI Reports Extended Disease Control Data in Neuroendocrine Tumor Study Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) reported four-year follow-up results from a first-in-human clinical study of its Freesolve resorbable magnesium coronary scaffold, providing long-term safety data as the company …
Teleflex Reports Four-Year Data for Resorbable Heart Scaffold Read More
NEWTOWN, PA — Traws Pharma Inc. (NASDAQ: TRAW) has deferred a planned Phase 2a human influenza challenge study of its lead antiviral candidate tivoxavir marboxil after receiving unfavorable feedback from …
Traws Delays Influenza Study After UK Regulatory Setback Read More